QuantaMatrix, Seoul, South Korea
https://www.quantamatrix.com/ 

QuantaMatrix Inc. is developing its rapid diagnostic platform to detect sepsis, especially in vulnerable neonates. The test aims to deliver results within just 6 hours from very small blood samples of 1 to 2 milliliters. If successful, the diagnostic could significantly improve patient outcomes as existing diagnostic methods can take several days. The BARNARDS study estimated that 2.5 million neonates or infants in the first month of life die annually of sepsis. Since neonatal sepsis progresses rapidly, it requires immediate treatment with IV fluids and antibiotics. The risk of death from neonatal sepsis increases 7.6% every hour a treatment is delayed.

QuantaMatrix is applying its rapid blood culture technology directly from whole blood, with the addition of a brief enrichment step and its multi-marker QMAP “One-pot Assay” to address technological challenges that have limited innovation in this space. With minimal sample processing and a large commercial footprint, this program could make testing for neonatal sepsis more accessible, globally.

Current Development Stage: Feasibility

CARB-X Investment: US$2.85 million

Initial CARB-X Investment Date: August 28, 2025